Synairgen (SNG.L) Shares Could Go Sky-High : The Drug Sng001 Has Shown Its Effectiveness

Synairgen shares have risen sharply this year. The growth of the stock from the beginning of the year to the present time was 5.5%. The lowest point of the fall was in May, falling from 148 pence to a minimum of 98 pence. But in June, the shares soared by 176. Despite this volatility, the company’s shares are still up almost 400% over the past 12 months. Today, Synairgen shares are worth 150 1.56% higher than yesterday’s value. Currently, the company’s future depends on the success of its inhaled drug beta-interferon, which is being tested as a potential treatment for coronavirus. The company’s treatment, SNG001, has shown its effectiveness in initial studies, but there is still a long way to go before full commercialization.

Towards the end of May, the company informed the market that a test of the drug SNG001 showed its effectiveness against SARS-CoV-2 variants. Commenting on the results of the tests, Professor Sir Stephen Holgate, founder of Synairgen, said that studies have confirmed the effect of interferon on viruses, which is a positive point for treatment and only increases its attractiveness for medical professionals.

Want Hot Stocks?    Yes. I Love Them No thanks